

Conflict: Healthcare Delivery and Methodologies.

Date: July 16, 2018.

Time: 2:00 p.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).

Contact Person: Karin F. Helmers, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3166, MSC 7770, Bethesda, MD 20892, 301-254-9975, helmersk@csr.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: June 8, 2018.

Sylvia L. Neal,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2018-12839 Filed 6-14-18; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive Patent Commercialization License: Streptococcus Pneumonia PSAA Peptide for Treatment of Sepsis and Infection

AGENCY: National Institutes of Health, Centers for Disease Control and Prevention, Department of Health and Human Services.

ACTION: Notice.

SUMMARY: The National Institute of Allergy and Infectious Diseases, an institute of the National Institutes of Health, Department of Health and Human Services, on behalf of the Centers for Disease Control and Prevention, Department of Health and Human Services, is contemplating the grant of an exclusive patent commercialization license to The University of Liverpool, located in Liverpool, UK, to practice the inventions embodied in the patent applications listed in the Supplementary Information section of this notice.

DATES: Only written comments and/or applications for a license which are received by the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases on or before July 2, 2018 will be considered.

ADDRESSES: Requests for copies of the patent applications, inquiries, and

comments relating to the contemplated exclusive patent commercialization license should be directed to: Karen Surabian, Licensing and Patenting Manager, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Suite 6D, MSC9804, Rockville, MD 20852-9804, phone number 301-496-2644, or karen.surabian@nih.gov.

SUPPLEMENTARY INFORMATION: The following represents the intellectual property to be licensed under the prospective agreement: United States Provisional Patent Application Number 61/085,208, filed 07/31/2008, entitled “Methods of Enhancing Opsonophagocytosis in Response to a Pathogen” (HHS Reference No. E-329-2013/0-US-01); PCT Patent Application Number PCT/US2009/052384, filed 07/31/2009, entitled “Methods of Enhancing Opsonophagocytosis in Response to a Pathogen” (HHS Reference No. E-329-2013/0-PCT-02); China Patent Number 200980137625.X, issued 11/26/2014, entitled “Methods of Enhancing Opsonophagocytosis in Response to a Pathogen” (HHS Reference No. E-329-2013/0-CN-03); European Patent Number 2323684, issued 05/21/2014, entitled “Use of a Pneumococcal P4 Peptide for Enhancing Opsonophagocytosis in Response to a Pathogen” (HHS Reference No. E-329-2013/0-EP-04), and validated in Germany, Spain, France, the United Kingdom, and Ireland; Hong Kong Patent Number 1160391, issued 07/31/2015, entitled “Methods of Enhancing Opsonophagocytosis in Response to a Pathogen” (HHS Reference No. E-329-2013/0-HK-05); United States Patent Number 8,431,134, issued 04/30/2013, entitled “Use of a Pneumococcal P4 Peptide for Enhancing Opsonophagocytosis in Response to a Pathogen” (HHS Reference No. E-329-2013/0-US-06); United States Patent Number 9,101,582, issued 08/11/2015, entitled “Use of a Pneumococcal P4 Peptide for Enhancing Opsonophagocytosis in Response to a Pathogen” (HHS Reference No. E-329-2013/0-US-07); United States Provisional Patent Application Number 60/682,495, filed 05/19/2005, entitled “Functional Epitopes of Streptococcus Pneumonia PSAA Antigen and Uses Thereof” (HHS Reference No. E-338-2013/0-US-01); PCT Patent Application Number PCT/US2005/027290, filed 07/29/2005, entitled “Functional Epitopes of Streptococcus Pneumonia PSAA Antigen and Uses Thereof” (HHS Reference No. E-338-2013/0-PCT-02); Australia Patent Number 2005332058,

issued 03/15/2012, entitled “Functional Epitopes of Streptococcus Pneumonia PSAA Antigen and Uses Thereof” (HHS Reference No. E-338-2013/0-AU-03); European Patent Number 1931700, issued 07/17/2003, entitled “Functional Epitopes of Streptococcus Pneumonia PSAA Antigen and Uses Thereof” (HHS Reference No. E-338-2013/0-EP-04), and validated in: Germany, Spain, France, the United Kingdom, and Ireland; Hong Kong Patent Number 1115144, issued 02/14/2014, entitled “Functional Epitopes of Streptococcus Pneumonia PSAA Antigen and Uses Thereof” (HHS Reference No. E-338-2013/0-HK-05); United States Patent Number 7,919,104, issued 04/05/2011, entitled “Functional Epitopes of Streptococcus Pneumonia PSAA Antigen and Uses Thereof” (HHS Reference No. E-338-2013/0-US-06); Canada Patent Application Number 2,631,556, filed 09/15/2014, entitled “Functional Epitopes of Streptococcus Pneumonia PSAA Antigen and Uses Thereof” (HHS Reference No. E-338-2013/0-CA-07); Australia Patent Number 2012201107, issued 06/06/2013, entitled “Functional Epitopes of Streptococcus Pneumonia PSAA Antigen and Uses Thereof” (HHS Reference No. E-338-2013/0-AU-08); Hong Kong Patent Number HK1163113, issued 06/05/2015, entitled “Functional Epitopes of Streptococcus Pneumonia PSAA Antigen and Uses Thereof” (HHS Reference No. E-338-2013/0-HK-09); European Patent Number 2371843, issued 09/17/2014, entitled “Functional Epitopes of Streptococcus Pneumonia PSAA Antigen and Uses Thereof” (HHS Reference No. E-338-2013/0-EP-10), and validated in: Germany, France, and the United Kingdom.

All rights in these inventions have been assigned to the Government of the United States of America.

The prospective exclusive patent commercialization license territory may be worldwide and the field of use may be limited to: “Development, manufacture, and sale of a P4 peptide therapeutic for the treatment of infection and sepsis.”

These inventions, developed within the National Center for Immunization and Respiratory Diseases (NCIRD), at the Centers for Disease Control and Prevention (CDC), describe methods to bolster the human body’s own mechanisms to fight infection by enhancing an innate immune response, opsonophagocytosis. The specific 24 amino acid peptide sequence (P4) acts as a polymorphonuclear cell activator. P4 can be administered in vivo along with disease-specific antibodies to enhance systemic bacterial clearance,

thus leading to prolonged survival. This technology enhances the body's response to a variety of bacterial infections, including *S. pneumoniae* and *S. aureus*.

This notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive patent commercialization license will be royalty bearing and may be granted unless within fifteen (15) days from the date of this published notice, the National Institute of Allergy and Infectious Diseases receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.

Complete applications for a license in the prospective field of use that are timely filed in response to this notice will be treated as objections to the grant of the contemplated exclusive patent commercialization license. In response to this Notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially, and may be made publicly available. License applications submitted in response to this Notice will be presumed to contain business confidential information, and any release of information in these license applications will be made only as required and upon a request under the *Freedom of Information Act*, 5 U.S.C. 552.

Dated: June 11, 2018.

Suzanne M. Frisbie,

Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases.

[FR Doc. 2018-12838 Filed 6-14-18; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the joint meeting of the National Cancer Advisory Board and NCI Board of Scientific Advisors, June 26, 2018, 8:30 a.m. to June 27, 2018, 12:00 p.m., National Cancer Institute Shady Grove, 9609 Medical Center Drive, Conference Room TE 406/408, Rockville, MD 20850 which was published in the **Federal Register** on June 05, 2018, 83 FR 26069.

This meeting notice is being amended to update the meeting locations for the National Cancer Advisory Board *Ad Hoc*

Subcommittee meetings. The National Cancer Advisory Board *Ad Hoc* Subcommittee Population Science, Epidemiology and Disparities meeting on June 25, 2018, 5:30 p.m. to 7:30 p.m., will be held at the Gaithersburg Marriott Washingtonian Center in Salons A and B. The National Cancer Advisory Board *Ad Hoc* Subcommittee on Global Cancer Research meeting on June 25, 2018, 7:30 p.m. to 9:00 p.m., will be held at the Gaithersburg Marriott Washingtonian Center in Salon C.

Dated: June 11, 2018.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2018-12837 Filed 6-14-18; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Agency Information Collection Activities: Submission for OMB Review; Comment Request

Periodically, the Substance Abuse and Mental Health Services Administration (SAMHSA) will publish a summary of information collection requests under OMB review, in compliance with the Paperwork Reduction Act (44 U.S.C. chapter 35). To request a copy of these documents, call the SAMHSA Reports Clearance Officer on (240) 276-1243.

Project: Survey of State Underage Drinking Prevention Policies and Practices—(OMB No. 0930-0316)—Revision

The *Sober Truth on Preventing Underage Drinking Act* (the “STOP Act”) (Pub. L. 109-422, reauthorized in 2016 by Pub. L. 114-255) states that the “Secretary [of Health and Human Services] shall . . . annually issue a report on each state’s performance in enacting, enforcing, and creating laws, regulations, and programs to prevent or reduce underage drinking.” The Secretary has delegated responsibility for this report to SAMHSA. Therefore, SAMHSA has developed a *Survey of State Underage Drinking Prevention Policies and Practices* (the “*State Survey*”) to provide input for the state-by-state report on prevention and enforcement activities related to underage drinking component of the *Annual Report to Congress on the Prevention and Reduction of Underage Drinking* (“*Report to Congress*”).

The STOP Act also requires the Secretary to develop “a set of measures

to be used in preparing the report on best practices” and to consider categories including but not limited to the following:

Category #1: Sixteen specific underage drinking laws/regulations enacted at the state level (e.g., laws prohibiting sales to minors; laws related to minors in possession of alcohol). Note that ten additional policies have been added to the Report to Congress pursuant to Congressional appropriations language or the Secretary’s authority granted by the STOP Act;

Category #2: Enforcement and educational programs to promote compliance with these laws/regulations;

Category #3: Programs targeted to youths, parents, and caregivers to deter underage drinking and the number of individuals served by these programs;

Category #4: The amount that each state invests, per youth capita, on the prevention of underage drinking broken into five categories: (a) Compliance check programs in retail outlets; (b) Checkpoints and saturation patrols that include the goal of reducing and deterring underage drinking; (c) Community-based, school-based, and higher-education-based programs to prevent underage drinking; (d) Underage drinking prevention programs that target youth within the juvenile justice and child welfare systems; and (e) Any other state efforts or programs that target underage drinking.

Congress’ purpose in mandating the collection of data on state policies and programs through the *State Survey* is to provide policymakers and the public with otherwise unavailable but much needed information regarding state underage drinking prevention policies and programs. SAMHSA and other Federal agencies that have underage drinking prevention as part of their mandate use the results of the *State Survey* to inform federal programmatic priorities, as do other stakeholders, including community organizations. The information gathered by the *State Survey* has established a resource for state agencies and the general public for assessing policies and programs in their own state and for becoming familiar with the programs, policies, and funding priorities of other states.

Because of the broad scope of data required by the STOP Act, SAMHSA relies on existing data sources where possible to minimize the survey burden on the states. SAMHSA uses data on state underage drinking policies from the National Institute of Alcohol Abuse and Alcoholism’s Alcohol Policy Information System (APIS), an authoritative compendium of state